Rophael John A, Craft Randall O, Palmer Jason A, Hussey Alan J, Thomas Gregory P L, Morrison Wayne A, Penington Anthony J, Mitchell Geraldine M
Bernard O'Brien Institute of Microsurgery, St Vincent's Hospital, 42 Fitzroy St., Fitzroy, Victoria, 3065, Australia.
Am J Pathol. 2007 Dec;171(6):2048-57. doi: 10.2353/ajpath.2007.070066. Epub 2007 Nov 30.
De novo tissue generation stimulated by three angiogenic growth factors administered in a factorial design was studied in an in vivo murine tissue engineering chamber. A silicone chamber was implanted around the epigastric pedicle and filled with Matrigel with 100 ng/ml of recombinant mouse vascular endothelial growth factor-120 (VEGF120), recombinant human basic fibroblastic growth factor (FGF-2), or recombinant rat platelet-derived growth factor-BB (PDGF-BB) added as single, double, or triple combinations. Angiogenesis, supporting tissue ingrowth, and adipogenesis were assessed at 2 and 6 weeks by immunohistochemistry and morphometry. At 2 weeks angiogenesis was synergistically enhanced by VEGF120 + FGF-2 (P = 0.019). FGF-2 (P = 0.008) and PDGF-BB (P = 0.01) significantly increased connective tissue/inflammatory cell infiltrate (macrophages, pericytes, and preadipocytes) in double and triple combinations compared with control. At 6 weeks sequential addition of growth factors increased the percent volume of adipose tissue (P < 0.0005, each main effect), with a synergistic increase in adipose tissue in combination treatments (P < 0.0005). Groups containing 300 ng/ml of single growth factors produced significantly less adipose tissue than the triple growth factor combination (P < 0.0005, VEGF120 and PDGF-BB; P < 0.001, FGF-2). In conclusion, angiogenic growth factor combinations increased early angiogenesis and cell infiltration resulting in synergistically increased adipose tissue growth at 6 weeks. Two way and higher level synergies are likely to be important in therapeutic applications of angiogenic growth factors.
在体内小鼠组织工程腔室中研究了以析因设计施用的三种血管生成生长因子刺激的新生组织生成。将硅胶腔室植入腹上蒂周围,并用添加了100 ng/ml重组小鼠血管内皮生长因子-120(VEGF120)、重组人碱性成纤维细胞生长因子(FGF-2)或重组大鼠血小板衍生生长因子-BB(PDGF-BB)的基质胶填充,作为单一、双重或三重组合添加。在第2周和第6周通过免疫组织化学和形态计量学评估血管生成、支持组织向内生长和脂肪生成。在第2周,VEGF120 + FGF-2协同增强了血管生成(P = 0.019)。与对照组相比,FGF-2(P = 0.008)和PDGF-BB(P = 0.01)在双重和三重组合中显著增加了结缔组织/炎症细胞浸润(巨噬细胞、周细胞和前脂肪细胞)。在第6周,生长因子的顺序添加增加了脂肪组织的体积百分比(每个主效应P < 0.0005),联合治疗中脂肪组织协同增加(P < 0.0005)。含有300 ng/ml单一生长因子的组产生的脂肪组织明显少于三重生长因子组合(VEGF120和PDGF-BB,P < 0.0005;FGF-2,P < 0.001)。总之,血管生成生长因子组合增加了早期血管生成和细胞浸润,导致第6周脂肪组织生长协同增加。双向和更高水平的协同作用可能在血管生成生长因子的治疗应用中很重要。